Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07545811 | Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer | PHASE1 | RECRUITING | 43 | — | — | Apr 15, 2026 | Mar 1, 2029 | Apr 22, 2026 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | JANX014 will be administered at increasing dose levels per cohort to determine the maximum tolerated dose. |
| Dose Expansion | EXPERIMENTAL | Participants will be dosed at levels previously declared tolerable. |
| Name | Type | Description |
|---|---|---|
| JANX014 | BIOLOGICAL | JANX014 will be administered via IV dosing |
Inclusion Criteria: * Male ≥18 years of age at the time of signing informed consent * Histologically or cytologically confirmed adenocarcinoma of the prostate * For Dose Escalation: Having mCRPC that progressed after at least one novel anti-androgen therapy and at least one taxane containing regime...